Evidence map›Paper›PMID 34854378›Full record

ArticleeLife2021

Single-cell-level protein analysis revealing the roles of autoantigen-reactive B lymphocytes in autoimmune disease and the murine model.

Takemichi Fukasawa, Ayumi Yoshizaki, Satoshi Ebata, Asako Yoshizaki-Ogawa, Yoshihide Asano, Atsushi Enomoto, Kiyoshi Miyagawa, Yutaka Kazoe, Kazuma Mawatari, Takehiko Kitamori and 1 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Room temperature quantitative liquid concentration device and application to interleukins analysis in a B-cell culture medium.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025
    Article
  8. Article
  9. Pathogenesis of interstitial lung disease in systemic sclerosis.Rheumatology and immunology research · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Impaired Regulation by IL-35 in Systemic Sclerosis.International journal of molecular sciences · 2023
    Article
  19. The Impact ofAntioxidants (Basel, Switzerland) · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Takemichi FukasawaDepartment of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.ORCID 0000-0002-6093-1881
Ayumi Yoshizaki *Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.ORCID 0000-0002-8194-9140
Satoshi EbataDepartment of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Asako Yoshizaki-OgawaDepartment of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Yoshihide AsanoDepartment of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Atsushi EnomotoLaboratory of Radiology and Biomedical Engineering, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Kiyoshi MiyagawaLaboratory of Radiology and Biomedical Engineering, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Yutaka KazoeDepartment of System Design Engineering, Keio university, Faculty of Science and technology, Tokyo, Japan.
Kazuma MawatariDepartment of Applied Chemistry, The University of Tokyo Graduate School of Engineering, Tokyo, Japan.
Takehiko KitamoriDepartment of Mechanical Engineering, The University of Tokyo Graduate School of Engineering, Tokyo, Japan.
Shinichi Sato *Department of Dermatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.ORCID 0000-0001-5519-172X
The University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite antigen affinity of B cells varying from cell to cell, functional analyses of antigen-reactive B cells on individual B cells are missing due to technical difficulties. Especially in the field of autoimmune diseases, promising pathogenic B cells have not been adequately studied to date because of its rarity. In this study, functions of autoantigen-reactive B cells in autoimmune disease were analyzed at the single-cell level. Since topoisomerase I is a distinct autoantigen, we targeted systemic sclerosis as autoimmune disease. Decreased and increased affinities for topoisomerase I of topoisomerase I-reactive B cells led to anti-inflammatory and pro-inflammatory cytokine production associated with the inhibition and development of fibrosis, which is the major symptom of systemic sclerosis. Furthermore, inhibition of pro-inflammatory cytokine production and increased affinity of topoisomerase I-reactive B cells suppressed fibrosis. These results indicate that autoantigen-reactive B cells contribute to the disease manifestations in autoimmune disease through their antigen affinity.

Indexed as

DNA Topoisomerases, Type IAdultAnimalsAutoantigensB-LymphocytesCytokinesDisease Models, AnimalFemaleFibrosisHumansMaleMiceMiddle AgedScleroderma, SystemicAutoantigensCytokinesDNA Topoisomerases, Type IB cellcytokinefibrosishumanimmunologyinflammationmousesingle cell analysissystemic sclerosis

Identifiers

PMID34854378
PMCPMC8639144
OpenAlexW3214823747

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.